BioSpace News Archive

FDA

FDA Approves Merck’s RECARBRIO™ For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration has approved RECARBRIO™ for injection, 1.25 grams, a new combination antibacterial.

July 17, 2019
·
10 min read
Drug Development

EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38α Kinase Inhibitor Neflamapimod on the Neurodegenerative Process

Presentations at Late Breaker Session at Alzheimer’s Association International Conference (AAIC) 2019

July 17, 2019
·
3 min read
Drug Development

Marker Therapeutics to Host Conference Call and Webcast to Review Interim Results from Phase 1/2 Clinical Trial with its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma

Marker Therapeutics, Inc. announced it will host a conference call and webcast with a question-and-answer session on Monday, July 22, 2019 at 5:30 a.m. PDT/ 8:30 a.m. EDT to review data from an investigator-sponsored Phase 1/2 clinical trial with its MultiTAA therapy in patients with pancreatic adenocarcinoma.

July 17, 2019
·
3 min read
BioMidwest

Humanity Life Extension, LLC Announces The Humility® Cancer Treatment, a Breakthrough Metastatic Cancer Solution

Humanity Life Extension, LLC announced a breakthrough metastatic cancer treatment known as The Humility® Cancer Treatment.

July 17, 2019
·
5 min read
MYM Closes Second Tranche of Non-Brokered Private Placement

MYM Nutraceuticals Inc., (CSE: MYM) (CSE: MYM.CN) (OTCBB: MYMMF) (“MYM” or “The Company”) announces it has closed the second tranche of its non-brokered private placement announced on July 5, 2019 of 2,528,174 units at a price of $0.324 for gross proceeds of $819,128. Included in this tranche is a drawdown on the Alumina Equity Agreement for $497,137.

July 17, 2019
·
3 min read
Drug Development

Elios Therapeutics Announces Positive Top-Line Data from Phase IIb Study Evaluating TLPLDC, a Personalized Therapeutic Cancer Vaccine, in Patients with High-Risk Melanoma

Elios Therapeutics, today announced positive top-line results from the Company’s prospective, randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating its lead immuno-oncology candidate, the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine, in patients with Stage III and IV resected melanoma.

July 17, 2019
·
8 min read
U.S. FDA Accepts Allergan’s New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension

Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Bimatoprost Sustained-Release (SR).

July 17, 2019
·
6 min read
Deals

Sobi Publishes Report for Second Quarter 2019

Swedish Orphan Biovitrum AB announces its results for the second quarter 2019.

July 17, 2019
·
5 min read
Business

Immusoft Announces the Appointment of Robert Hayes, Ph.D. as Chief Scientific Officer

Experienced leader in biotech platform development, Dr. Hayes to head research and advancement of ISP™ platform

July 17, 2019
·
5 min read
Deals

Orum Therapeutics Announces $30 Million Series B Financing to Advance Cell-Penetrating, Cell-Specific Antibody Technology for Novel Therapeutics

Financing proceeds to fund further platform development and therapeutic discovery in cancer and rare diseases, and expansion of Orum’s new Boston R&D labs

July 17, 2019
·
2 min read